Boehringer Ingelheim v. Sun Pharma: JARDIANCE® Patent Dispute Settled After 2,182 Days
Boehringer Ingelheim pursued patent infringement claims against Sun Pharmaceutical Industries over US10258637B2, protecting its blockbuster SGLT2 inhibitor JARDIANCE® (empagliflozin) and combination tablet GLYXAMBI®. After nearly six years and consolidation across nine related Delaware actions, the parties reached a negotiated resolution in July 2025.
Nine consolidated ANDA actions, one negotiated exit: the JARDIANCE® patent saga
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, and Boehringer Ingelheim Pharmaceuticals, Inc. filed suit against Sun Pharmaceutical Industries, Inc. and affiliated entity Ohm Laboratories, Inc. in the District of Delaware on August 9, 2019, asserting infringement of US10258637B2. The patent, filed under application number US15/918401, protects empagliflozin formulations commercialised as JARDIANCE® tablets and the empagliflozin/linagliptin combination product GLYXAMBI®. The action is a classic Hatch-Waxman ANDA dispute: Sun’s filing of an abbreviated new drug application triggered Boehringer’s 30-month stay window and subsequent litigation.
The case closed on July 30, 2025, after the parties agreed to a negotiated resolution spanning this action and eight further related Delaware cases, ultimately consolidated across three separate docket clusters. The public record describes the outcome as a settlement with agreed terms and conditions but does not disclose the commercial substance — whether Sun received a licence, an agreed entry date, or other consideration remains undisclosed. The basis of termination is formally recorded as ‘Case Consolidated’, reflecting the procedural vehicle through which the unified resolution was entered.
A duration of 2,182 days — nearly six years — is notably long even for complex ANDA litigation. The breadth of consolidation across nine actions filed between 2018 and 2021 suggests Boehringer pursued an aggressive multi-wave enforcement strategy as Sun filed successive ANDAs on related products and formulations. The negotiated exit, without a reported trial verdict, is consistent with the commercial reality that JARDIANCE® remains a high-value asset; settlement terms likely reflect market entry timing rather than a concession on patent validity.
Filing to Case Consolidated in 2182 days
Nearly 6 years — well above the median ANDA patent litigation duration in Delaware
Negotiated resolution: what the settlement means for both parties
Why ‘Case Consolidated’ is the formal termination basis
When multiple related ANDA actions settle simultaneously, courts often enter a single consent order or dismissal through the lead consolidated docket. Here, the formal termination basis reflects that procedural vehicle — the underlying substance is a private settlement agreement. The public docket confirms mutual agreement on ‘terms and conditions representing a negotiated resolution’ but does not reproduce those terms.
Consolidated settlementBoehringer retains control over JARDIANCE® market entry timing
A negotiated resolution in Hatch-Waxman litigation almost always involves a negotiated entry date for the generic — potentially years before patent expiry. Boehringer’s ability to coordinate settlement across nine consolidated actions suggests it maintained leverage throughout. Without a reported consent judgement of non-infringement or invalidity, US10258637B2 remains formally undefeated in this dispute. The patent’s enforceability against other potential generic filers is unaffected by this private resolution.
Patent intact, entry date negotiatedSun secures a negotiated path to market — terms undisclosed
Sun Pharmaceutical and Ohm Laboratories avoided a potentially adverse trial outcome by settling. The agreed terms likely include a licensed entry date for their empagliflozin ANDA products. Whether Sun obtained a royalty-bearing licence, a royalty-free entry after a specific date, or other commercial consideration is not reflected in the public record. The settlement is consistent with Sun preserving its ANDA investment while accepting Boehringer’s framework for generic entry.
Agreed entry date likelyJARDIANCE® generic competition: controlled timeline, not open market
JARDIANCE® (empagliflozin) carries substantial commercial value as a leading SGLT2 inhibitor with cardiovascular and renal indications. A privately negotiated settlement controls the timing of generic entry in a way that a court ruling could not. For other ANDA filers watching this docket, the settlement signals that Boehringer will enforce its portfolio vigorously and may offer structured entry rather than litigate to judgment. The GLYXAMBI® combination product adds further complexity to any future FTO analysis.
Structured generic entryFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Pharmaceutical innovator — holder of US10258637B2 covering empagliflozin (JARDIANCE®)Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for empagliflozin tabletsSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Ohm Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text confirms a private negotiated resolution across nine consolidated Delaware actions involving Boehringer Ingelheim and Sun Pharmaceutical. The language — ‘agreed to terms and conditions representing a negotiated resolution’ — is a standard recital in Hatch-Waxman consent orders and deliberately withholds commercial substance. No finding of infringement, validity, or non-infringement was entered, meaning the resolution carries no precedential weight on claim construction or patent scope. Both parties retain their legal positions as a matter of public record.
US10258637B2 — empagliflozin formulations (JARDIANCE® and GLYXAMBI®)
US10258637B2, filed under application number US15/918401, protects pharmaceutical formulations of empagliflozin — a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes, heart failure, and chronic kidney disease. The patent underpins both JARDIANCE® (empagliflozin alone) and GLYXAMBI® (empagliflozin in combination with the DPP-4 inhibitor linagliptin), giving Boehringer Ingelheim layered formulation protection across its empagliflozin franchise. SGLT2 inhibitor patents in this class are high-value assets given the class’s multi-indication regulatory profile.
Empagliflozin is among the most commercially significant SGLT2 inhibitors globally, with JARDIANCE® generating multi-billion dollar annual revenues. Patent protection on the formulation — rather than solely the active compound — is a common innovator strategy to extend effective market exclusivity beyond the base compound patent. For generic manufacturers, this means navigating a dense IP thicket: compound, formulation, method-of-use, and combination patents may each independently block ANDA approval. The breadth of Boehringer’s enforcement across nine consolidated actions demonstrates the commercial stakes attached to this specific formulation patent.
Should you run an FTO analysis against US10258637B2?
Any company developing, manufacturing, or commercialising empagliflozin tablet formulations — whether as a standalone SGLT2 inhibitor or in combination with a DPP-4 inhibitor such as linagliptin — should treat US10258637B2 as a primary FTO concern. The settlement here does not establish a public claim construction, meaning the patent’s full claim scope remains untested by any court ruling. Generic and biosimilar developers, contract manufacturers, and combination product filers in this space all carry direct exposure.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10258637B2 against your candidate formulation, identify prosecution history estoppel, and surface related Boehringer family members that may assert parallel coverage. Eureka also tracks live ANDA litigation dockets across Delaware and other jurisdictions, giving your IP team real-time visibility into Boehringer’s enforcement posture before you file.
Run a freedom-to-operate analysis on US10258637B2 to assess your product’s exposure
Run FTO in Eureka →Related SGLT2 inhibitor and ANDA patent cases in Delaware District Court
Explore comparable Hatch-Waxman ANDA patent infringement actions involving SGLT2 inhibitor formulations litigated in the District of Delaware.
What this case signals for the SGLT2 inhibitor patent IP landscape
Nine actions, six years, one private deal: Boehringer’s enforcement posture over empagliflozin carries clear lessons for ANDA filers and innovators alike.
Multi-wave ANDA enforcement is a deliberate Boehringer strategy
The consolidation of nine related Delaware actions — filed across 2018–2021 — reflects a layered enforcement approach as Sun filed successive ANDAs on empagliflozin and its combinations. Generic challengers entering this space should anticipate Boehringer filing promptly on each new ANDA, triggering multiple overlapping 30-month stays and compounding litigation costs.
Settlement without validity ruling leaves US10258637B2 fully enforceable
Because no court ruled on validity or non-infringement, US10258637B2 emerges from this litigation without any adverse finding. Future ANDA filers cannot rely on this case as precedent. An IPR or inter partes review remains a potential strategy for challengers seeking to neutralise the patent before filing an ANDA, though Boehringer’s litigation history suggests it will respond aggressively.
Boehringer-Ingelheim v Sun — key questions answered
The case settled via a negotiated resolution entered on July 30, 2025. The parties agreed to terms covering this action and eight further consolidated Delaware cases. The commercial substance of the agreement — including any licensed entry date for Sun’s empagliflozin ANDA products — is not disclosed in the public record.
The case asserts US10258637B2 (application no. US15/918401), a patent covering empagliflozin tablet formulations. The patent protects both JARDIANCE® (empagliflozin) and GLYXAMBI® (empagliflozin/linagliptin combination) products marketed by Boehringer Ingelheim.
Consolidation is standard practice when a brand pharmaceutical company files successive infringement suits as a generic challenger submits multiple ANDAs over time. Boehringer filed actions from 2018 through 2021 across different patent claims and products; the court consolidated these into three docket clusters before Judge Connolly to manage common questions of law and fact efficiently.
No. The settlement entered no finding on validity, enforceability, or infringement. US10258637B2 remains formally unchallenged by any court ruling arising from this litigation. Other generic filers cannot rely on this settlement as precedent for any claim construction or validity argument.
GLYXAMBI® (empagliflozin/linagliptin) is a combination product separately asserted in this litigation alongside JARDIANCE®. Its inclusion signals that Boehringer protects the combination formulation as a distinct asset, meaning ANDA filers targeting the combination must conduct independent FTO analysis — claim scope for combination product patents may differ materially from single-agent formulation claims.
PatSnap Eureka searches patents and litigation data to answer instantly.